title: Inhibitors of C5 complement enhance vaccinia virus oncolysis.
abstract: Genetically engineered tumor-selective vaccinia virus (VV) has been demonstrated to be a highly effective oncolytic agent, but immune clearance may limit its therapeutic potential. As previously demonstrated, immunosuppression can lead to significant enhancement of viral recovery and therapeutic effect, but the magnitude of complement-mediated viral inactivation has not been fully elucidated and warrants further investigation. Using fluorescent microscopy and quantitative plaque assays, we have determined complement's key role in viral clearance and its multi-faceted means to pathogen destruction. Complement can lead to direct viral destruction and inhibition of viral uptake into cells, even in the absence of anti-vaccinia antibodies. Our data demonstrate C5 to be integral to the clearance pathway, and its inhibition by Staphylococcal superantigen-like protein leads to a 90-fold and 150-fold enhancement of VV infectivity in both the presence and absence of anti-VV antibodies, respectively. This study suggests that complement inhibition may reduce vaccinia viral neutralization and may be critical to future in vivo work.
authors: Department of Surgery, University of Pittsburgh School of Medicine and Medical Center, Pittsburgh, PA 15213, USA. maggedr@upmc.edu
authors: D
authors: D
authors: Magge
authors: Z S
authors: ZS
authors: Guo
authors: M E
authors: ME
authors: O'Malley
authors: L
authors: L
authors: Francis
authors: R
authors: R
authors: Ravindranathan
authors: D L
authors: DL
authors: Bartlett
mesh_terms: D000914:Antibodies, Viral / Q000235:genetics / Q000276:immunology; D002460:Cell Line; D003182:Complement C5 / Q000037:antagonists & inhibitors*; D006801:Humans; D007165:Immunosuppression Therapy; D050130:Oncolytic Virotherapy; D050504:Oncolytic Viruses / Q000235:genetics* / Q000276:immunology; D014616:Vaccinia virus / Q000235:genetics* / Q000276:immunology
chemical_list: D000914:Antibodies, Viral; D003182:Complement C5
references: Mol Ther. 2011 Apr;19(4):650-7
references: 21266959
references: Curr Top Microbiol Immunol. 1990;153:235-48
references: 1688755
references: Mol Ther. 2007 Jan;15(1):123-30
references: 17164783
references: Proc Natl Acad Sci U S A. 2010 Feb 23;107(8):3681-6
references: 20133685
references: Lancet Oncol. 2008 Jun;9(6):533-42
references: 18495536
references: J Virol. 2007 Apr;81(7):3487-94
references: 17202212
references: Adv Exp Med Biol. 2008;632:273-92
references: 19025129
references: Cytokine Growth Factor Rev. 2010 Apr-Jun;21(2-3):177-83
references: 20219409
references: J Biosci. 2003 Apr;28(3):265-71
references: 12734405
references: Proc Natl Acad Sci U S A. 1992 Jan 15;89(2):628-32
references: 1731333
references: Mol Immunol. 1996 Dec;33(17-18):1389-401
references: 9171898
references: Cancer Res. 2001 Dec 15;61(24):8751-7
references: 11751395
references: Nat Biotechnol. 2012 Jul 10;30(7):658-70
references: 22781695
references: Eur J Immunol. 1981 Feb;11(2):140-6
references: 6163641
references: J Gen Virol. 2002 Jan;83(Pt 1):209-222
references: 11752718
references: Nat Immunol. 2004 Oct;5(10):971-4
references: 15454919
references: Mol Immunol. 2011 Aug;48(14):1631-42
references: 21549429
references: Nat Med. 1999 Aug;5(8):881-7
references: 10426310
references: Gene Ther. 2003 Jun;10(11):983-90
references: 12756419
references: Nature. 2011 Aug 31;477(7362):99-102
references: 21886163
references: Cancer Gene Ther. 2002 Dec;9(12):1001-12
references: 12522439
references: Clin J Am Soc Nephrol. 2008 Mar;3 Suppl 2:S101-16
references: 18308998
references: Lancet. 1998 Feb 28;351(9103):610-1
references: 9500312
references: Adv Exp Med Biol. 1998;440:395-414
references: 9782308
references: Cancer Treat Rev. 2011 Dec;37(8):618-32
references: 21232872
references: Cancer. 1974 Oct;34(4 Suppl):suppl:1474-80
references: 4608289
references: PLoS Pathog. 2008 Dec;4(12):e1000249
references: 19112490
references: Cancer Res. 2008 Apr 1;68(7):2071-5
references: 18381410
references: Biochim Biophys Acta. 2008 Apr;1785(2):217-31
references: 18328829
references: J Biosci. 2003 Apr;28(3):249-64
references: 12734404
references: Clin Cancer Res. 2009 Apr 15;15(8):2777-88
references: 19351762
references: Nat Rev Microbiol. 2008 Feb;6(2):132-42
references: 18197169
references: Proc Natl Acad Sci U S A. 1995 Sep 12;92(19):8955-9
references: 7568051
references: Gene Ther. 2010 Dec;17(12):1465-75
references: 20703311
references: J Virol. 2000 May;74(10):4765-75
references: 10775615
references: Nat Rev Cancer. 2009 Jan;9(1):64-71
references: 19104515
references: Proc Natl Acad Sci U S A. 1987 Oct;84(19):6854-8
references: 3477812
references: Acta Crystallogr D Biol Crystallogr. 2001 Apr;57(Pt 4):596-8
references: 11264593
references: Nat Immunol. 2004 Oct;5(10):981-6
references: 15454921
references: Annu Rev Biochem. 1990;59:661-88
references: 2197987
references: J Immunol. 2009 Sep 1;183(5):3150-9
references: 19667083
references: Clin Diagn Lab Immunol. 2003 Nov;10(6):982-9
references: 14607856
references: Nat Rev Immunol. 2009 Jun;9(6):418-28
references: 19461672